Journals / Turkish journal of nephrology (Online) / 2021 / Cilt: 30 - Sayı: 2

Screening for Fabry Disease in Patients Who Underwent Renal Biopsy and Identification of a Novel Mutation

Pages
165–170
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With the importance of early diagnosis, we screened FD among proteinuric patients in whom biopsy findings revealed Fabry nephropathy.Methods: Patients with light microscopic biopsy findings of vacuolated cells, focal and/or segmental glomerular sclerosis, tubular atrophy, and interstitial fibrosis were not associated with particular etiology, the presence of acro-paresthesia, angiokeratomas, and cornea verticillata, stroke history younger than 50 years, family history of renal failure with no cardiovascular risk factors were screened.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The X-linked Fabry disease (FD) with lysosomal storage of globotriaosylceramide (Gb3) due to α-galactosidase deficiency contributes to nephropathy consisting of proteinuria and renal failure eventually.
📊
Key Findings & Data:With the importance of early diagnosis, we screened FD among proteinuric patients in whom biopsy findings revealed Fabry nephropathy.Methods: Patients with light microscopic biopsy findings of vacuolated cells, focal and/or segmental glomerular sclerosis, tubular atrophy, and interstitial fibrosis were not associated with particular etiology, the presence of acro-paresthesia, angiokeratomas, and cornea verticillata, stroke history younger than 50 years, family history of renal failure with no cardiovascular risk factors were screened.
💡
Conclusion & Impact:Two of 37 males had low enzyme activity ( A) p.(Trp349*)).Conclusion: It is worth noting that FD screening in patients with proteinuria, in whom vacuolated cells, mesangial expansion, glomerulosclerosis, interstitial fibrosis, and tubular atrophy of unknown etiology, are present in the renal biopsy either with or without a family history of kidney disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: The X-linked Fabry disease (FD) with lysosomal storage of globotriaosylceramide (Gb3) due to α-galactosidase deficiency contributes to nephropathy consisting of proteinuria and renal failure eventually. Early initiation of the enzyme replacement therapy promises favorable renal outcomes. With the importance of early diagnosis, we screened FD among proteinuric patients in whom biopsy findings revealed Fabry nephropathy.Methods: Patients with light microscopic biopsy findings of vacuolated cells, focal and/or segmental glomerular sclerosis, tubular atrophy, and interstitial fibrosis were not associated with particular etiology, the presence of acro-paresthesia, angiokeratomas, and cornea verticillata, stroke history younger than 50 years, family history of renal failure with no cardiovascular risk factors were screened. Fifty-three of 308 consecutive adult patients (45.34 ± 15.23 years old, 60.1% male) who underwent renal biopsy because of proteinuria were enrolled in the study. Screening for FD was performed by assessing α-Gal A activity in dried blood spots (DBS) for males and by genetic testing for females.Results: Fifty-three patients (39.94 ± 11.97 years, 69.8% male) who underwent renal biopsy were screened. Laboratory findings revealed mean serum creatinine of 1.44 ± 1.06 mg/dL, mean estimated glomerular filtration rate of 78.31 ± 39.89 mL/min/1.73 $m^2$, and mean proteinuria of 4.32 ± 3 g/day, whereas the females genetic screening was negative. Two of 37 males had low enzyme activity ( A) p.(Trp349*)).Conclusion: It is worth noting that FD screening in patients with proteinuria, in whom vacuolated cells, mesangial expansion, glomerulosclerosis, interstitial fibrosis, and tubular atrophy of unknown etiology, are present in the renal biopsy either with or without a family history of kidney disease.

🔖

Cite This Article

ORUÇ, A., YILDIZ, A., AKGÜR, S., ÜNSAL, O., AYDIN, M. F., ERSOY, A., YAVUZ, M., DİLEK, K., GÜLLÜLÜ, M. (2021). Screening for Fabry Disease in Patients Who Underwent Renal Biopsy and Identification of a Novel Mutation. Turkish journal of nephrology (Online), Cilt: 30 - Sayı: 2, 165–170. https://ajindex.com/articles/374786

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. [CrossRef] 2. Sanchez-Niño MD, Sanz AB, Carrasco S, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011;26(6):1797- 1802. [CrossRef] 3. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Investig. 2004;34(3):236-242. [CrossRef] 4. Branton MH, Schiffmann R, Sabnis SG. et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine. 2002;81(2):122- 138. [CrossRef] 5. Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631-1641. [CrossRef] 6. Terryn W, Cochat P, Froissart R, et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant. 2013;28(3):505-517. [CrossRef] 7. Ortiz A, Cianciaruso B, Cizmarik M, et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant. 2010;25(3):769-775. [CrossRef] 8. Najafian B, Svarstad E, Bostad L, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 2011;79(6):663-670. [CrossRef] 9. Meehan SM, Junsanto T, Rydel JJ, Desnick RJ. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. Am J Kidney Dis. 2004;43(1):164-171. [CrossRef] 10. Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004;15(5):1323-1329. [CrossRef] 11. Nishino T, Obata Y, Furusu A, et al. Identification of a novel mutation and prevalence study for Fabry disease in Japanese dialysis patients. Ren Fail. 2012;34(5):566-570. [CrossRef] 12. Okur I, Ezgu F, Biberoglu G, et al. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation. Gene. 2013;527(1):42-47. [CrossRef] 13. Yeniçerioğlu Y, Akdam H, Dursun B, et al. Screening Fabry’s disease in chronic kidney disease patients not on dialysis: a multicenter study. Ren Fail. 2017;39(1):104-111